NEOPATH AUTOPAP AUTOMATED PAP SMEAR ANALYZER RECOMMENDED FOR PRIMARY SCREENING; DEVICE SUPERIOR TO MANUAL REVIEW IN DETECTING ABNORMALITIES
This article was originally published in The Gray Sheet
Additional data submitted as part of NeoPath's premarket approval application supplement for use of the AutoPap automated cervical cytology reader as a primary screener of Pap smear slides are adequate to support approval, FDA's Hematology and Pathology Devices panel unanimously (8-0) recommended at a Jan. 28 meeting in Rockville, Maryland. The panel said the PMA for the device, which would identify certain slides as not requiring a manual evaluation, should be approved with conditions.
You may also be interested in...
Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.